SCHEMBL650949

SCHEMBL650949

CC(=O)Nc1ncc(C=C2SC(=Nc3cccc(O)c3C)NC2=O)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 1/20 0.48
MAPT P10636 8/20 0.46
NPSR1 Q6W5P4 4/20 0.46
MEN1 O00255 8/20 0.45
KMT2A Q03164 8/20 0.45
MAPK1 P28482 2/20 0.45
RNASEL Q05823 2/20 0.41
PTP4A3 O75365 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
POLB P06746 3/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
BLM P54132 1/20 0.39
MCL1 Q07820 1/20 0.39
PLA2G1B P04054 1/20 0.39
APEX1 P27695 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650948 1.00 GRK6 (0.48) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL649866 0.92 GRK6 (0.45) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL650934 0.92 MAPT (0.56) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL651471 0.92 GRK6 (0.45) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL650933 0.92 MAPT (0.56) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL651180 0.92 MEN1 (0.43) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL651181 0.92 MEN1 (0.43) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL650328 0.89 MAPT (0.44) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL649994 0.89 MAPT (0.44) GRK6MAPTNPSR1MEN1KMT2A
SCHEMBL649023 0.89 MEN1 (0.46) GRK6MAPTNPSR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 GRK6 1322/4885MAPT 3657/4885NPSR1 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.